IN8BIO, INC. Logo

IN8BIO, INC.

Clinical-stage biopharma developing gamma-delta T cell therapies for cancer.

INAB | US

Overview

Corporate Details

ISIN(s):
US45674E1091
LEI:
Country:
United States of America
Address:
EMPIRE STATE BUILDING, 10118 NEW YORK

Description

IN8BIO, INC. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of gamma-delta T cell therapies for solid and hematological tumors. The company's proprietary DeltEx™ platform utilizes allogeneic, autologous, and genetically modified approaches to develop novel cell therapies. IN8BIO was the first to advance genetically modified gamma-delta T cells into clinical trials. Its lead product candidates include INB-400, a Phase 2 asset for newly diagnosed glioblastoma (GBM), and INB-100, a Phase 1 candidate for patients with leukemia undergoing hematopoietic stem cell transplantation. The company is also advancing a broad portfolio of preclinical programs focused on solid tumors.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Filters

Clear
Bulk Actions:
Select rows to enable
Date Filing Language Type / Size Actions
2024-12-15
English
4.2 MB
2024-10-30
German
1.8 MB
2024-08-14
French
0.5 MB
2024-05-22
English
2.1 MB
2024-03-10
English
3.5 MB
2024-01-15
German
1.2 MB
2023-11-20
English
5.1 MB

Full Filing History Restricted

Access to specific historical documents or filtered results is limited in the Web UI. Request access to the complete dataset.

Automate Your Workflow. Get a real-time feed of all IN8BIO, INC. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for IN8BIO, INC.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for IN8BIO, INC. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

CKD Bio Corp. Logo
Develops APIs, intermediates, and probiotics using fermentation and synthesis.
South Korea
063160
Clearmind Medicine Inc. Logo
Clinical-stage psychedelic pharma firm developing treatments for Alcohol Use Disorder.
United States of America
CMND
Clearside Biomedical, Inc. Logo
Biopharmaceutical firm with an FDA-approved microinjector for back-of-the-eye delivery.
United States of America
CLSD
Clene Inc. Logo
A clinical-stage biopharma developing nanotherapeutics for neurodegenerative diseases.
United States of America
CLNN
CMG Pharmaceutical Co., Ltd. Logo
A pharmaceutical firm specializing in Oral Thin Film drug delivery technology.
South Korea
058820
CNS Pharmaceuticals, Inc. Logo
Develops anti-cancer drug candidates for cancers of the brain and nervous system.
United States of America
CNSP
Cocrystal Pharma, Inc. Logo
Clinical-stage biotech developing antiviral drugs for serious and chronic viral diseases.
United States of America
COCP
Co-Diagnostics, Inc. Logo
A molecular diagnostics company that develops and markets advanced PCR technologies.
United States of America
CODX
co.don AG Logo
Develops autologous cell therapies for regenerative treatment of cartilage defects.
Germany
CNW
Coeptis Therapeutics Holdings, Inc. Logo
Biopharmaceutical company developing cell therapy platforms for cancer and other diseases.
United States of America
COEP

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.